For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 6,487,909 | |||
| Research and development | 9,802,807 | |||
| Total operating expenses | 16,290,716 | |||
| Unrealized gain | 3,980 | |||
| Realized and accrued interest income | 482,081 | |||
| Total other income | 486,061 | |||
| Net loss | -15,804,655 | |||
| Foreign currency translation | -613 | |||
| Total other comprehensive loss | -613 | |||
| Comprehensive loss | -15,805,268 | |||
| Basic EPS | -14.8 | |||
| Diluted EPS | -14.8 | |||
| Basic Average Shares | 1,068,152 | |||
| Diluted Average Shares | 1,068,152 | |||
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)